Singapore Market Roundup (10-Apr-2026): DBS rates Wee Hur Holdings a 'buy' at 90 cents target.
DBS rates Wee Hur Holdings as 'buy' with a 90 cents target price. PhillipCapital resumes iX Biopharma coverage with a $1 target. New hospital won't...
206 Views
Health Horizons: Singapore's Rising Stars in Biotech & Medtech
Singapore’s healthcare and life sciences sector presents a compelling structural growth opportunity in 2026. In our view, two complementary...
169 Views
Singapore Market Roundup (23-Feb-2026): PhillipCapital and UOB KayHian keep 'buy' on United
PhillipCapital and UOB KayHian keep 'buy' on United Hampshire US REIT. Maybank and RHB are positive on Marco Polo Marine. JP Morgan raises CICT...
226 Views
Singapore Market Roundup (10-Feb-2026): OCBC raises Boustead Singapore's fair value to $2.45.
OCBC raises Boustead Singapore's fair value to $2.45; DBS and RHB maintain 'buy' on Elite UK REIT; OCBC lowers Sheng Siong to 'hold' but raises...
354 Views
Singapore Market Roundup (30-Jan-2026): CSE Global rated 'buy' by Beansprout, target $1.40.
Beansprout rates CSE Global 'buy' at $1.40. DBS lifts Nam Cheong to $1.60, labeling it a 'hidden gem.' CGSI keeps 'add' on Genting SG for earnings...
269 Views